A Phase 1 interventional study of Gepotidacin in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-21.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.
Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 7th largest by enrollment, is one of 2 that started in 2016, is one of 9 in phase 1, and was the 4th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2016.
This study's enrollment of 32 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 34 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Bacterial Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 29 finished, 13 (45%) have results posted.
Among the 35 studies in Bacterial Infections by GlaxoSmithKline, this one is the 16th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2016, is one of 28 in phase 1, and was the 24th registered.
GlaxoSmithKline’s Bacterial Infections studies by the year they started, since 2005.
1 of the studies testing gepotidacin in Bacterial Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing gepotidacin in Bacterial Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Bacterial Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be conducted to determine if altered renal function affects the plasma pharmacokinetics of gepotidacin, which will inform if dosing recommendations based upon renal impairment are required. The objective of this study is to compare the pharmacokinetics of gepotidacin administered as a 750 milligram (mg) intravenous (IV) dose in normal healthy subjects compared with subjects with mild, moderate, and severe renal impairment, and with subjects with end stage renal disease (ESRD). This is a Phase I, nonrandomized, open-label, parallel-group, multi-center, multi-part study. In Part 1, up to 16 subjects with normal renal function will be matched to approximately 8 subjects with moderate renal impairment, and approximately 8 subjects with severe renal impairment and/or subjects with ESRD not on hemodialysis for a total of approximately 32 subjects. In Part 2 (optional), approximately 4 to 8 subjects with normal renal function (if enrolled), approximately 4 to 8 subjects with mild renal impairment, and approximately 4 to 8 subjects with ESRD on hemodialysis will be enrolled for a total of approximately 12 to 24 subjects. The duration from Screening to the Follow-up Visit will be approximately 44 days for Part 1 and approximately 50 days for Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Nonreproductive potential defined as:
and agrees to follow 1 of the options listed in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential requirements from 30 days prior to the first dose until completion of the Follow-up Visit.
For subjects with indeterminate pregnancy test results or a persistently low human chorionic gonadotropin results, nonpregnancy status must be documented by other means (subjects with ESRD only).
Exclusion Criteria:
Subject has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study drug, or any other condition that may place the subject at risk, in the opinion of the investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
Drug: Gepotidacin
Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
Drug: Gepotidacin
Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
Drug: Gepotidacin
Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
Drug: Gepotidacin
Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
Drug: Gepotidacin
Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).
Drug: Gepotidacin
Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1
AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity . Blood samples were collected at the indicated time-points, during the study. The Pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. The PK Population consisted of all participant's, who received at least 1 dose of gepotidacin and had evaluable PK data.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
AUC (0-inf) of Gepotidacin for Part 2
AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for gepotidacin. Blood samples were collected at the indicated time-points, during the study.
Time frame: Pre-dose, 0.25 hours, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Maximum Observed Plasma Concentration (Cmax) of Gepotidacin for Part 1
Cmax, is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected, at the indicated time points for analysis of gepotidacin.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Cmax of Gepotidacin for Part 2
Cmax, is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected, at the indicated time points for analysis of gepotidacin.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on during treatment period 1 and 2 both.
Total Amount Excreted in Urine (Ae Total), Part 1
Urine samples from the participants were collected during the study. Ae total assessed the, total unchanged drug (total amount of drug excreted in urine), which was calculated, by adding all the fractions of drug gepotidacin collected, at the indicated time points. No formal statistical analysis of group comparison was planned for urine PK parameters.
Time frame: Pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period
Ae Total of Gepotidacin for Part 2
Urine samples, from the participants were collected during the study. Ae total assessed the, total unchanged drug (total amount of drug excreted in urine), which was calculated, by adding all the fractions of drug gepotidacin collected, at the indicated time points. Urine samples were collected at pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period. Only those participant's available at the specified time points were analyzed. No formal statistical analysis of group comparison was planned for urine PK parameters.
Time frame: Pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during both treatment period 1 and 2
Percentage of the Given Dose Excreted in Urine (fe%) of Gepotidacin for Part 1
The fe% measured the percentage of the given dose of drug gepotidacin, excreted in urine. It was calculated as: Ae total divided by the dose administered multiplied by 100.
Time frame: At pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period
fe% of Gepotidacin for Part 2
The fe% measured the percentage of the given dose of drug gepotidacin, excreted in urine. It was calculated as: Ae total divided by the dose administered multiplied by 100. No formal statistical analysis of group comparison was planned for urine PK parameters. Only those participants available at the specified time points were analyzed.
Time frame: At pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods
Renal Clearance (CLr) of Gepotidacin for Part 1
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time via renal clearance pathways, expressed as volume (Liter) per unit of time (hour). The renal clearance was calculated by Ae total divided by AUC from hour 0 to the last measurable plasma concentration AUC (0-t). Urine samples were collected at pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period. No formal statistical analysis of group comparison was planned for urine PK parameters.
Time frame: At pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period
CLr of Gepotidacin for Part 2
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time via renal clearance pathways, expressed as volume (Liter) per unit of time (hour). Urine samples were collected at pre-dose (0.0), 0 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods. Only those participant's available at the specified time points were analyzed. No formal statistical analysis of group comparison was planned for urine PK parameters.
Time frame: At pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods
AUC (t0-t1) of Gepotidacin for Part 2
Partial area under the curve estimated from predialyzer samples collected from start of dialysis (t0) to end of dialysis (t1). Only applicable to Part 2 ESRD on hemodialysis (before hemodialysis) arm..
Time frame: Dialysate fluid were to be collected on Day 1 after dosing (Period 1 only) at pre-dose from 0 to 4 hours
Dialysis Clearance (CLD) of Gepotidacin for Part 2
CLD measured the dialysis clearance of gepotidacin over the specified duration in the study and indicates how quickly gepotidacin is cleared out from blood or plasma. Only applicable to Part 2 ESRD on hemodialysis (before hemodialysis) arm.
Time frame: Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1
Fraction (%) of the Dose Removed by Hemodialysis From 0 to 4 Hours After the Start of Hemodialysis (Frem%[0-4]) of Gepotidacin for Part 2
Dialysate samples were collected at specified time points in the study. Frem is defined as the fraction (dose in percentage) removed by the process of hemodialysis from 0 to 4 hours after the start of hemodialysis (or to the end of dialysis if less than 4 hours)
Time frame: Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Readings for Part 1
Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and corrected Q to T interval (QTc). The data for abnormal ECG recordings not clinically significant (NCS) and clinically significant (CS), have been reported at specific timepoints during the study. No formal analysis of group comparison was planned for dialysate PK parameters
Time frame: Up to 16 Days
Number of Participants With Abnormal 12-lead ECG Readings for Part 2
Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and corrected Q to T interval (QTc). The data for abnormal ECG recordings not clinically significant (NCS) and clinically significant (CS), have been reported at specific time points during the study. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). NA indicates data was not available
Time frame: Up to 23 Days
Change From Baseline in Vitals- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure, Part 1
Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for systolic blood pressure (SBP) and diastolic blood pressure (DBP) was reported. Baseline was defined as the latest pre-dose assessment. Change from Baseline, was defined as post Baseline values minus the values at Baseline.
Time frame: Baseline and up to 16 Days
Change From Baseline in Vitals- SBP and DBP, Part 2
Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for systolic blood pressure (SBP) and diastolic blood pressure (DBP) was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to 23 Days
Change From Baseline in Vitals- Pulse Rate, Part 1
Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for pulse rate was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment
Time frame: Baseline and up to 16 Days
Change From Baseline in Vitals- Pulse Rate, Part 2
Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for pulse rate was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and Up to 23 Days
Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) for Part 1
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.
Time frame: Up to 16 Days
Number of Participants With Any AEs and Any SAEs for Part 2
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.
Time frame: Up to 23 Days
Number of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 1
The adverse events reported by the participants were classified as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 as life-threatening. The data for clinical laboratory findings with values of Grade 3 or higher, have been reported.
Time frame: Up to 17 Days
Number of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 2
The adverse events reported by the participants were classified as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 as life-threatening. The data for clinical laboratory findings with values of Grade 3 or higher, have been reported.
Time frame: Up to 24 Days
Number of Participants With Abnormal Physical Examination Results for Part 1
Physical exam were to be performed by a qualified individual. A complete physical examination included, at a minimum, an assessment of the cardiovascular, respiratory, GI, and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This data was not collected.
Time frame: Up to 16 Days
Number of Participants With Abnormal Physical Examination Results for Part 2
Physical exam were to be performed by a qualified individual. A complete physical examination included, at a minimum, an assessment of the cardiovascular, respiratory, GI, and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This data was not collected.
Time frame: Up to 23 Days
AUC (0-t) of Gepotidacin for Part 1
Blood samples were collected at specified time-points for PK analysis. The data for Area under the concentration-time curve from time 0 (predose) to time of last quantifiable concentration for gepotidacin were reported.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
AUC (0-t) of Gepotidacin for Part 2
Serial blood samples were collected at specified time-points for PK analysis. The data for Area under the concentration-time curve from time 0 (predose) to time of last quantifiable concentration for gepotidacin were reported.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Systemic Clearance (CL) of Gepotidacin for Part 1
Serial blood samples were collected at specified time-points for PK analysis. Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-inf).
Time frame: At pre-dose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose during the single treatment period.
CL of Gepotidacin for Part 2
Serial blood samples were collected at specified time-points for PK analysis. Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-inf).
Time frame: At pre-dose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose in each of the two treatment periods
Terminal Elimination Rate Constant (lambda_z) of Gepotidacin for Part 1
Serial blood samples were collected at specified time-points for PK analysis. It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Lambda_z of Gepotidacin for Part 2
Serial blood samples were collected at specified time-points for PK analysis. It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose on during treatment period 1 and 2 both
Terminal Phase Half-life (t1/2) of Gepotidacin for Part 1
Serial blood samples were collected at specified time-points for PK analysis. t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
t1/2 of Gepotidacin for Part 2
Serial blood samples were collected at specified time-points for PK analysis. t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Time to Maximum Plasma Concentration (Tmax) of Gepotidacin for Part1
Serial blood samples were collected at specified time-points for PK analysis. Tmax was defined as the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Tmax of Gepotidacin for Part 2
Serial blood samples were collected at specified time-points for PK analysis. Tmax was defined as the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Volume of Distribution at Steady State of Parent Drug (Vss) of Gepotidacin for Part 1
Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Vss of Gepotidacin for Part 2
Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Volume of Distribution of the Terminal Phase (Vz) of Gepotidacin for Part 1
Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz is the apparent volume of distribution at terminal phase. Volume of distribution of the terminal phase was calculated as total administered dose of gepotidacin divided by AUC (0-inf) multiplied by the rate constant.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Vz of Gepotidacin for Part 2
Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz is the apparent volume of distribution at terminal phase. Volume of distribution of the terminal phase was calculated as total administered dose of gepotidacin divided by AUC (0-inf) multiplied by the rate constant.
Time frame: Pre-dose, 0.25 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose during treatment period 1 and 2 both.
Cumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Normal
Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participant's with normal renal function.
Time frame: At Pre-dose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours
Cumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Moderate and Severe
Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: at pre-dose (0.0), 0 to 6 hours, 6 to 12 hours, 12 to 24 hours, 24 to 36, and 36 to 48 hours post-dose during the single treatment period
Ae(t1-t2) of Gepotidacin for Part 2
Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participant's with normal renal function. NA indicates data is not available due to insufficient participants.Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during both treatment period 1 and 2
Total Amount of Unchanged Amount of Drug Removed by Hemodialysis (Arem) From Time 0 to 1 Hour After the Start of Hemodialysis (Arem[0-1]), Arem (1-2), Arem (2-3), Arem (3-4) for Part 2
Arem is defined as the total amount of drug removed using the hemodialysis method at different timepoints namely Arem (0-1), measured the amount of drug removed by hemodialysis from time 0 to 1 hour after the start of hemodialysis; Arem (1-2), measured the amount of drug removed by hemodialysis from time 1 to 2 hours after the start of hemodialysis; Arem(2-3) ), measured the amount of drug removed by hemodialysis from time 2 to 3 hour, Arem (3-4), measured the amount of drug removed by hemodialysis from hemodialysis from time 3 to 4 hours after the start of hemodialysis (or to the end of dialysis if \<4 hours). Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Pre-dose, 0-1 hours, 1-2 hours, 2-3 hours and 3-4 hours post-dose on Day 1 in Period 1Dialysate fluid were collected at 1, 2, 3, and 4 hours post-dose in Period 1 only
A 2-part study, conducted in participant's with varying degree of renal impairment (RI) which enrolled 32 participants, wherein, 24 participants were enrolled in Part 1 and 8 participants in Part 2. The study was conducted, at 3 centers in United States of America from 29 June 2016 to 20 June 2017.
| Milestone | Normal, Part 1 | Moderate | Severe/ESRD Not on Hemodialysis, Part 1 | ESRD on Hemodialysis, Part 2 |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 0 |
| Completed | 8 | 8 | 8 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Normal, Part 1 | Moderate | Severe/ESRD Not on Hemodialysis, Part 1 | ESRD on Hemodialysis, Part 2 |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 8 |
| Completed | 0 | 0 | 0 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity . Blood samples were collected at the indicated time-points, during the study. The Pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. The PK Population consisted of all participant's, who received at least 1 dose of gepotidacin and had evaluable PK data.
| Nanogram*hour per milliliter | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 | 14838 ± 20.7 | 22367 ± 17.0 | 28545 ± 21.4 |
AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for gepotidacin. Blood samples were collected at the indicated time-points, during the study.
| Nanogram*hour per milliliter | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| AUC (0-inf) of Gepotidacin for Part 2 | 14838 ± 20.7 | 35239 ± 95.0 | 60461 ± 140.5 |
Cmax, is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected, at the indicated time points for analysis of gepotidacin.
| nanogram per milliliter | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Gepotidacin for Part 1 | 4498 ± 16.3 | 5306 ± 16.0 | 7084 ± 23.3 |
Cmax, is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected, at the indicated time points for analysis of gepotidacin.
| nanogram per milliliter | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| Cmax of Gepotidacin for Part 2 | 4498 ± 16.3 | 10123 ± 216.3 | 26839 ± 797.1 |
Urine samples from the participants were collected during the study. Ae total assessed the, total unchanged drug (total amount of drug excreted in urine), which was calculated, by adding all the fractions of drug gepotidacin collected, at the indicated time points. No formal statistical analysis of group comparison was planned for urine PK parameters.
| milligram. | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Total Amount Excreted in Urine (Ae Total), Part 1 | 280.49 ± 15.2 | 165.86 ± 39.4 | 59.40 ± 68.3 |
Urine samples, from the participants were collected during the study. Ae total assessed the, total unchanged drug (total amount of drug excreted in urine), which was calculated, by adding all the fractions of drug gepotidacin collected, at the indicated time points. Urine samples were collected at pre-dose (0.0), 0 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period. Only those participant's available at the specified time points were analyzed. No formal statistical analysis of group comparison was planned for urine PK parameters.
| milligram | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| Ae Total of Gepotidacin for Part 2 | 280.49 ± 15.2 | 7.87 ± 96.4 | 10.87 ± 64.7 |
The fe% measured the percentage of the given dose of drug gepotidacin, excreted in urine. It was calculated as: Ae total divided by the dose administered multiplied by 100.
| Percentage of gepotidacin | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Percentage of the Given Dose Excreted in Urine (fe%) of Gepotidacin for Part 1 | 37.40 ± 15.2 | 22.11 ± 39.4 | 7.92 ± 68.3 |
The fe% measured the percentage of the given dose of drug gepotidacin, excreted in urine. It was calculated as: Ae total divided by the dose administered multiplied by 100. No formal statistical analysis of group comparison was planned for urine PK parameters. Only those participants available at the specified time points were analyzed.
| Percentage of gepotidacin | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| fe% of Gepotidacin for Part 2 | 37.40 ± 15.2 | 1.05 ± 96.4 | 1.45 ± 64.7 |
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time via renal clearance pathways, expressed as volume (Liter) per unit of time (hour). The renal clearance was calculated by Ae total divided by AUC from hour 0 to the last measurable plasma concentration AUC (0-t). Urine samples were collected at pre-dose (0.0), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose during the single treatment period. No formal statistical analysis of group comparison was planned for urine PK parameters.
| Liter per hour | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Renal Clearance (CLr) of Gepotidacin for Part 1 | 19.24 ± 18.8 | 7.58 ± 44.3 | 2.13 ± 84.3 |
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time via renal clearance pathways, expressed as volume (Liter) per unit of time (hour). Urine samples were collected at pre-dose (0.0), 0 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours post-dose in each of the two treatment periods. Only those participant's available at the specified time points were analyzed. No formal statistical analysis of group comparison was planned for urine PK parameters.
| Liter per hour | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| CLr of Gepotidacin for Part 2 | 19.24 ± 18.8 | 0.29 ± 101.7 | 0.10 ± 277.5 |
Partial area under the curve estimated from predialyzer samples collected from start of dialysis (t0) to end of dialysis (t1). Only applicable to Part 2 ESRD on hemodialysis (before hemodialysis) arm..
| Nanogram*hour per milliliter | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| AUC (t0-t1) of Gepotidacin for Part 2 | — | 1062 ± 36.3 | — |
CLD measured the dialysis clearance of gepotidacin over the specified duration in the study and indicates how quickly gepotidacin is cleared out from blood or plasma. Only applicable to Part 2 ESRD on hemodialysis (before hemodialysis) arm.
| Liter per hour | ESRD on Hemodialysis (Before Hemodialysis), Part 2 |
|---|---|
| Dialysis Clearance (CLD) of Gepotidacin for Part 2 | 6.63 ± 15.8 |
Dialysate samples were collected at specified time points in the study. Frem is defined as the fraction (dose in percentage) removed by the process of hemodialysis from 0 to 4 hours after the start of hemodialysis (or to the end of dialysis if less than 4 hours)
| Percentage of gepotidacin removed | ESRD on Hemodialysis (Before Hemodialysis), Part 2 |
|---|---|
| Fraction (%) of the Dose Removed by Hemodialysis From 0 to 4 Hours After the Start of Hemodialysis (Frem%[0-4]) of Gepotidacin for Part 2 | 5.89 ± 26.2 |
Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and corrected Q to T interval (QTc). The data for abnormal ECG recordings not clinically significant (NCS) and clinically significant (CS), have been reported at specific timepoints during the study. No formal analysis of group comparison was planned for dialysate PK parameters
| Participants | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Baseline, Abnormal, NCS | 3 | 6 | 7 |
| Baseline, Abnormal, CS | 0 | 0 | 0 |
| Day 1 - 1.5 hour, Abnormal, NCS | 5 | 6 | 6 |
| Day 1- 1.5 hour, Abnormal, CS | 0 | 0 | 0 |
| Day 1- 2 hour, Abnormal, NCS | 3 | 6 | 6 |
| Day 1- 2 hour, Abnormal, CS | 0 | 0 | 0 |
| Day 1 - 4 hour, Abnormal, NCS | 2 | 6 | 7 |
| Day 1- 4 hour, Abnormal CS | 0 | 0 | 0 |
| Day 1 - 8 hour, Abnormal NCS | 2 | 6 | 6 |
| Day 1 - 8 hour, Abnormal, CS | 0 | 0 | 0 |
| Day 1 - 12 hour, Abnormal NCS | 2 | 6 | 7 |
| Day 1 - 12 hour, Abnormal, CS | 0 | 0 | 0 |
| Day 2 - 24 hour, Abnormal NCS | 3 | 7 | 5 |
| Day 2 - 24 hour, Abnormal, CS | 0 | 0 | 0 |
| Day 2 - 36 hour, Abnormal NCS | 2 | 6 | 6 |
| Day 2 - 36 hour, Abnormal, CS | 0 | 0 | 0 |
| Day 3 - 48 hour, Abnormal NCS | 2 | 6 | 5 |
| Day3 - 48 hour, Abnormal, CS | 0 | 0 | 0 |
| Follow-up, Abnormal NCS | 3 | 5 | 5 |
| Follow-up, Abnormal CS | 0 | 0 | 0 |
Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated the heart rate and measures PR, QRS, QT, and corrected Q to T interval (QTc). The data for abnormal ECG recordings not clinically significant (NCS) and clinically significant (CS), have been reported at specific time points during the study. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). NA indicates data was not available
| Participants | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|
| Day 1- Baseline, Abnormal CS (n=8,8) | 0 | 0 |
| Day 1 - Baseline, Abnormal NCS (n=8,8) | 6 | 7 |
| Day 1- 2 hour, Abnormal, NCS (n=8,0) | 6 | — |
| Day 1- 2 hour, Abnormal, CS (n=8,0) | 0 | — |
| Day 1 - 4 hour, Abnormal, NCS (n=8,0) | 7 | — |
| Day 1- 4 hour, Abnormal CS (n=8,0) | 0 | — |
| Day 1 - 8 hour, Abnormal NCS (n=8,0) | 7 | — |
| Day 1 - 8 hour, Abnormal, CS (n=8,0) | 0 | — |
| Day 1 - 12 hour, Abnormal NCS (n=8,0) | 6 | — |
| Day 1 - 12 hour, Abnormal, CS (n=8,0) | 0 | — |
| Day 2 - 24 hour, Abnormal NCS (n=8,0) | 7 | — |
| Day 2 - 24 hour, Abnormal, CS (n=8,0) | 0 | — |
| Day 2 - 36 hour, Abnormal NCS (n=8,0) | 8 | — |
| Day 2 - 36 hour, Abnormal, CS (n=8,0) | 0 | — |
| Day 3 - 48 hour, Abnormal NCS (n=8,0) | 7 | — |
| Day3 - 48 hour, Abnormal, CS (n=8,0) | 0 | — |
| Day 8- 2 hour, Abnormal, NCS (n=0,8) | — | 8 |
| Day 8- 2 hour, Abnormal, CS (n=0,8) | — | 0 |
| Day 8 - 4 hour, Abnormal, NCS (n=0,8) | — | 8 |
| Day 8- 4 hour, Abnormal CS (n=0,8) | — | 0 |
| Day 8 - 8 hour, Abnormal NCS (n=0,8) | — | 7 |
| Day 8 - 8 hour, Abnormal, CS (n=0,8) | — | 0 |
| Day 8 - 12 hour, Abnormal NCS (n=0,8) | — | 8 |
| Day 8 - 12 hour, Abnormal, CS (n=0,8) | — | 0 |
| Day 9- 24 hour, Abnormal, NCS (n=0,8) | — | 6 |
| Day 9- 24 hour, Abnormal, CS (n=0,8) | — | 0 |
| Day 9 - 36 hour, Abnormal, NCS (n=0,8) | — | 8 |
| Day 9- 36 hour, Abnormal CS (n=0,8) | — | 0 |
| Day 10 - 48 hour, Abnormal NCS (n=0,8) | — | 7 |
| Day 10 - 48 hour, Abnormal, CS (n=0,8) | — | 0 |
| Follow-up, Abnormal NCS (n=0,8) | — | 6 |
| Follow-up, Abnormal CS (n=0,8) | — | 0 |
Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for systolic blood pressure (SBP) and diastolic blood pressure (DBP) was reported. Baseline was defined as the latest pre-dose assessment. Change from Baseline, was defined as post Baseline values minus the values at Baseline.
| Milliliter of mercury | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| SBP, Day 1- 1.5 hour, | 3.1 ± 2.36 | 6.8 ± 11.94 | -3.3 ± 13.77 |
| SBP, Day 1- 2 hour, | 6.9 ± 12.54 | 8.3 ± 13.39 | -4.4 ± 12.73 |
| SBP, Day 1 - 4 hour | -0.9 ± 12.15 | 3.4 ± 5.42 | 1.0 ± 13.03 |
| SBP, Day 1 - 8 hour, | 1.3 ± 12.69 | 5.9 ± 7.30 | 6.0 ± 12.75 |
| SBP, Day 1 - 12 hour, | -3.4 ± 12.29 | 14.1 ± 12.89 | 4.6 ± 6.30 |
| SBP, Day 2 - 24 hour, | -1.1 ± 13.28 | 5.3 ± 6.65 | -4.1 ± 11.46 |
| SBP, Day 2 - 36 hour | 0.5 ± 3.74 | 14.4 ± 13.02 | -0.4 ± 9.12 |
| SBP, Day 3 - 48 hour | -1.0 ± 10.72 | 7.8 ± 9.10 | -6.0 ± 18.18 |
| SBP, Follow-up | 0.8 ± 3.28 | 8.3 ± 13.06 | -4.8 ± 18.16 |
| DBP, Day 1- 1.5 hour | 0.1 ± 3.91 | -1.3 ± 3.92 | -3.5 ± 7.19 |
| DBP, Day 1- 2 hour, | 5.8 ± 7.15 | 1.3 ± 3.99 | 0.4 ± 4.07 |
| DBP, Day 1 - 4 hour | 3.0 ± 5.50 | -2.4 ± 8.14 | 1.5 ± 4.99 |
| DBP, Day 1 - 8 hour | 4.9 ± 6.06 | -4.3 ± 10.55 | -2.4 ± 6.95 |
| DBP, Day 1 - 12 hour | 2.9 ± 6.36 | -0.5 ± 9.61 | -3.6 ± 4.66 |
| DBP, Day 2 - 24 hour | 2.3 ± 5.50 | 1.0 ± 5.55 | -2.3 ± 4.17 |
| DBP, Day 2 - 36 hour | 3.1 ± 8.22 | -0.8 ± 13.07 | -3.5 ± 3.96 |
| DBP, Day 3 - 48 hour | 5.0 ± 7.69 | 0.6 ± 6.48 | -5.3 ± 5.87 |
| DBP, Follow-up | 2.6 ± 5.48 | 0.5 ± 11.60 | -1.8 ± 6.58 |
Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for systolic blood pressure (SBP) and diastolic blood pressure (DBP) was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Milliliter of mercury | ESRD on Hemodialysis |
|---|---|
| SBP, Day 1- 2 hour, (n=8) | -0.5 ± 14.91 |
| SBP, Day 1 - 4 hour (n=8) | 8.6 ± 16.66 |
| SBP, Day 1 - 8 hour, (n=8) | -0.6 ± 23.93 |
| SBP, Day 1 - 12 hour, (n=8) | -4.8 ± 17.68 |
| SBP, Day 2 - 24 hour, (n=8) | 1.4 ± 9.69 |
| SBP, Day 2 - 36 hour (n=8) | 3.9 ± 10.33 |
| SBP, Day 3 - 48 hour, (n=8) | 6.5 ± 5.53 |
| SBP, Day 8-2 hour (n=8) | -2.0 ± 8.16 |
| SBP, Day 8-4 hour (n=8) | -4.4 ± 7.46 |
| SBP, Day 8-8 hour (n=8) | -14.8 ± 14.50 |
| SBP, Day 8-12 hour (n=6) | -8.3 ± 7.92 |
| SBP, Day 9-24 hour (n=8) | 5.9 ± 23.94 |
| SBP, Day 9-36 hour (n=8) | 2.3 ± 20.11 |
| SBP, Day 10-48 hour (n=8) | 12.6 ± 19.72 |
| SBP, Follow-up, (n=8) | 0.5 ± 11.86 |
| DBP, Day 1- 2 hour, (n=8) | 4.3 ± 11.31 |
| DBP, Day 1 - 4 hour, (n=8) | 3.6 ± 9.83 |
| DBP, Day 1 - 8 hour, (n=8) | -1.5 ± 11.70 |
| DBP, Day 1 - 12 hour (n=8) | -2.3 ± 9.54 |
| DBP, Day 2 - 24 hour (n=8) | 4.6 ± 9.68 |
| DBP, Day 2 - 36 hour,(n=8) | 3.3 ± 6.11 |
| DBP, Day 3 - 48 hour (n=7) | 3.0 ± 10.10 |
| DBP, Day 8-2 hour, (n=8) | -2.1 ± 10.49 |
| DBP, Day 8-4 hour , (n=8) | -2.5 ± 9.41 |
| DBP, Day 8- 8 hour,(n=8) | -6.9 ± 8.48 |
| DBP, Day 8-12 hour, (n=8) | -9.5 ± 10.03 |
| DBP, Day 9-24 hour, (n=8) | 6.4 ± 9.41 |
| DBP, Day 9-36 hour (n=8) | 2.6 ± 13.41 |
| DBP, Day 10-48 hour (n=8) | 5.9 ± 11.74 |
| DBP, Follow-up (n=8) | 2.3 ± 6.34 |
Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for pulse rate was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment
| Beats per minute | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Pulse rate, Day 1- 1.5 hour | 0.1 ± 9.28 | 1.6 ± 4.21 | 3.5 ± 4.41 |
| Pulse rate, Day 1- 2 hour | 1.8 ± 7.13 | 4.1 ± 3.23 | 4.1 ± 5.03 |
| Pulse rate, Day 1 - 4 hour | 0.1 ± 6.49 | 0.4 ± 8.14 | 2.0 ± 5.63 |
| Pulse rate, Day 1 - 8 hour | -1.0 ± 13.40 | 1.8 ± 7.50 | 0.8 ± 4.46 |
| Pulse rate, Day 1 - 12 hour | -0.1 ± 12.31 | 3.4 ± 4.78 | 3.4 ± 1.92 |
| Pulse rate, Day 2 - 24 hour | 1.0 ± 13.06 | -0.8 ± 7.85 | -2.3 ± 5.55 |
| Pulse rate, Day 2 - 36 hour | 1.6 ± 9.56 | -0.5 ± 5.37 | 0.6 ± 5.24 |
| Pulse rate, Day 3 - 48 hour | -1.4 ± 10.76 | -0.1 ± 7.88 | -1.8 ± 7.34 |
| Pulse rate, Follow-up | -0.6 ± 10.34 | 0.6 ± 8.45 | 0.0 ± 7.43 |
Vital signs were measured in semi-supine position after 5 minutes of rest. The data for change from Baseline values for pulse rate was reported. Change from Baseline, was defined as post Baseline values minus the values at Baseline. Baseline was defined as the latest pre-dose assessment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| beats per minute | ESRD on Hemodialysis |
|---|---|
| Pulse rate, Day 1- 2 hour, (n=8) | 0.4 ± 8.78 |
| Pulse rate, Day 1 - 4 hour, (n=8) | 3.4 ± 9.09 |
| Pulse rate, Day 1 - 8 hour, (n=8) | 4.4 ± 9.46 |
| Pulse rate, Day 1 - 12 hour, (n=7) | 4.4 ± 10.21 |
| Pulse rate, Day 2 - 24 hour, (n=8) | 2.5 ± 7.11 |
| Pulse rate, Day 2 - 36 hour, (n=8) | 6.1 ± 9.96 |
| Pulse rate, Day 3 - 48 hour, (n=7) | 3.6 ± 5.88 |
| Pulse rate, Day, 8-2 hour (n=8) | 4.8 ± 10.38 |
| Pulse rate, Day 8-4 hour (n=7) | 2.1 ± 5.08 |
| Pulse rate, Day 8-8 hour ,(n=8) | 3.4 ± 7.69 |
| Pulse rate, Day 8-12 hour (n=8) | 4.7 ± 10.05 |
| Pulse rate, Day 9-24 hour (n=8) | 4.0 ± 11.51 |
| Pulse rate, Day9-36 hour (n=8) | 8.9 ± 16.19 |
| Pulse rate, Day 10-48 hour (n=8) | 3.6 ± 11.04 |
| Pulse rate, Follow-up (n=8) | 3.8 ± 10.22 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.
| Participants | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Any SAE | 0 | 0 | 0 |
| Any AE | 0 | 3 | 4 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.
| Participants | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|
| Any SAE | 0 | 0 |
| Any AE | 4 | 3 |
The adverse events reported by the participants were classified as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 as life-threatening. The data for clinical laboratory findings with values of Grade 3 or higher, have been reported.
| Participants | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Serum or plasma creatinine, Grade 3 or higher | 0 | 0 | 5 |
| Serum glucose, Grade 3 or higher | 0 | 0 | 1 |
The adverse events reported by the participants were classified as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 as life-threatening. The data for clinical laboratory findings with values of Grade 3 or higher, have been reported.
| Participants | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|
| Serum or plasma creatinine, Grade 3 or higher | 8 | 0 |
| Serum glucose, Grade 3 or higher | 2 | 0 |
Physical exam were to be performed by a qualified individual. A complete physical examination included, at a minimum, an assessment of the cardiovascular, respiratory, GI, and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This data was not collected.
No measurements were reported for this outcome.
Physical exam were to be performed by a qualified individual. A complete physical examination included, at a minimum, an assessment of the cardiovascular, respiratory, GI, and neurological systems. Height and weight were also measured and recorded. A brief physical examination included, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). This data was not collected.
No measurements were reported for this outcome.
Blood samples were collected at specified time-points for PK analysis. The data for Area under the concentration-time curve from time 0 (predose) to time of last quantifiable concentration for gepotidacin were reported.
| Nanogram*hour per milliliter | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| AUC (0-t) of Gepotidacin for Part 1 | 14582 ± 20.8 | 21883 ± 17.1 | 27886 ± 21.4 |
Serial blood samples were collected at specified time-points for PK analysis. The data for Area under the concentration-time curve from time 0 (predose) to time of last quantifiable concentration for gepotidacin were reported.
| Nanogram*hour per milliliter | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| AUC (0-t) of Gepotidacin for Part 2 | 14582 ± 20.8 | 34633 ± 95.8 | 59311 ± 143.3 |
Serial blood samples were collected at specified time-points for PK analysis. Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-inf).
| Liter per hour | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Systemic Clearance (CL) of Gepotidacin for Part 1 | 50.55 ± 20.7 | 33.53 ± 17.0 | 26.27 ± 21.4 |
Serial blood samples were collected at specified time-points for PK analysis. Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-inf).
| Liter per hour | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| CL of Gepotidacin for Part 2 | 50.55 ± 20.7 | 21.28 ± 95.0 | 12.40 ± 140.5 |
Serial blood samples were collected at specified time-points for PK analysis. It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour.
| Per hour | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Terminal Elimination Rate Constant (lambda_z) of Gepotidacin for Part 1 | 0.06027 ± 11.9 | 0.06369 ± 16.1 | 0.06266 ± 13.4 |
Serial blood samples were collected at specified time-points for PK analysis. It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour.
| Per hour | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Lambda_z of Gepotidacin for Part 2 | 0.06027 ± 11.9 | 0.07338 ± 8.4 | 0.06428 ± 16.4 |
Serial blood samples were collected at specified time-points for PK analysis. t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.
| hours | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Terminal Phase Half-life (t1/2) of Gepotidacin for Part 1 | 11.663 (9.549 to 13.065) | 11.421 (7.402 to 12.259) | 11.246 (8.901 to 14.046) |
Serial blood samples were collected at specified time-points for PK analysis. t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.
| hours | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| t1/2 of Gepotidacin for Part 2 | 11.663 (9.549 to 13.065) | 9.455 (8.441 to 10.915) | 11.121 (8.275 to 12.896) |
Serial blood samples were collected at specified time-points for PK analysis. Tmax was defined as the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.
| hours | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Gepotidacin for Part1 | 2.000 (1.00 to 2.00) | 2.000 (1.50 to 2.00) | 2.000 (0.25 to 2.50) |
Serial blood samples were collected at specified time-points for PK analysis. Tmax was defined as the time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.
| hours | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| Tmax of Gepotidacin for Part 2 | 2.000 (1.00 to 2.00) | 2.000 (0.50 to 2.02) | 1.575 (0.25 to 2.00) |
Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
| Liter | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Volume of Distribution at Steady State of Parent Drug (Vss) of Gepotidacin for Part 1 | 255 ± 21.7 | 223 ± 14.8 | 181 ± 23.5 |
Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
| Liter | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| Vss of Gepotidacin for Part 2 | 255 ± 21.7 | 114 ± 335.6 | 49 ± 938.8 |
Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz is the apparent volume of distribution at terminal phase. Volume of distribution of the terminal phase was calculated as total administered dose of gepotidacin divided by AUC (0-inf) multiplied by the rate constant.
| Liter | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|---|
| Volume of Distribution of the Terminal Phase (Vz) of Gepotidacin for Part 1 | 839 ± 25.3 | 527 ± 29.1 | 419 ± 27.0 |
Serial blood samples were collected at specified time-points for PK analysis. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz is the apparent volume of distribution at terminal phase. Volume of distribution of the terminal phase was calculated as total administered dose of gepotidacin divided by AUC (0-inf) multiplied by the rate constant.
| Liter | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| Vz of Gepotidacin for Part 2 | 839 ± 25.3 | 290 ± 90.8 | 193 ± 161.3 |
Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participant's with normal renal function.
| milligram | Normal, Part 1 |
|---|---|
| Ae(0-2) | 135.53 ± 21.0 |
| Ae (2-4) | 59.95 ± 56.7 |
| Ae (4-6) | 19.90 ± 18.4 |
| Ae (6-8) | 19.47 ± 70.5 |
| Ae (8-12) | 9.11 ± 86.9 |
| Ae(12-24) | 12.30 ± 55.3 |
| Ae(24-36) | 5.38 ± 52.1 |
| Ae(36-48) | 3.00 ± 42.8 |
Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| milligram | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 |
|---|---|---|
| Ae (0-6) (n=8, 8) | 119.79 ± 50.0 | 39.54 ± 94.9 |
| Ae (6-12) (n=8, 8) | 21.67 ± 30.7 | 8.26 ± 44.8 |
| Ae (12-24) (n=8, 8) | 12.81 ± 40.8 | 4.42 ± 160.0 |
| Ae(24-36 (n=8, 8) | 5.25 ± 25.4 | 2.89 ± 29.8 |
| Ae(36-48) (n=8,7) | 2.66 ± 50.3 | 1.17 ± 71.0 |
Ae (t1-t2), measure the amount of drug excreted in urine in a time intervals for predose, 0 to 6, 6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hours after dosing for participant's with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours for participant's with normal renal function. NA indicates data is not available due to insufficient participants.Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| milligram | Normal, Part 1 | ESRD on Hemodialysis (Before Hemodialysis), Part 2 | ESRD on Hemodialysis (After Hemodialysis), Part 2 |
|---|---|---|---|
| Ae (0-8)(n=0,3,3) | — | 5.56 ± 123.4 | 8.12 ± 73.8 |
| Ae (8-12) (n=8,3,3) | 9.11 ± 86.9 | 0.72 ± 32.1 | 1.16 ± 31.5 |
| Ae (12-24) (n=8,3, 3) | 12.30 ± 55.3 | 0.81 ± 147.5 | 1.31 ± 52.5 |
| Ae (24-36) (n=8,2,1) | 5.38 ± 52.1 | 0.45 ± 154.4 | 0.75 ± NA |
| Ae (36-48) (n=8,2,0) | 3.00 ± 42.8 | 0.14 ± 133.2 | — |
Arem is defined as the total amount of drug removed using the hemodialysis method at different timepoints namely Arem (0-1), measured the amount of drug removed by hemodialysis from time 0 to 1 hour after the start of hemodialysis; Arem (1-2), measured the amount of drug removed by hemodialysis from time 1 to 2 hours after the start of hemodialysis; Arem(2-3) ), measured the amount of drug removed by hemodialysis from time 2 to 3 hour, Arem (3-4), measured the amount of drug removed by hemodialysis from hemodialysis from time 3 to 4 hours after the start of hemodialysis (or to the end of dialysis if \<4 hours). Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| milligram | ESRD on Hemodialysis (Before Hemodialysis), Part 2 |
|---|---|
| Arem (0-1), (n=8) | 18.22 ± 27.7 |
| Arem (1-2), (n=8) | 12.42 ± 34.8 |
| Arem (2-3), (n=8) | 8.93 ± 32.5 |
| Arem (3-4), (n=6) | 5.35 ± 36.6 |
Collected over AEs and SAEs were collected from the start of study treatment upto 94 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal, Part 1 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Moderate, Part 1 | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Severe/ESRD Not on Hemodialysis, Part 1 | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| ESRD on Hemodialysis (Before Hemodialysis) | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| ESRD on Hemodialysis (After Hemodialysis) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 | ESRD on Hemodialysis (Before Hemodialysis) | ESRD on Hemodialysis (After Hemodialysis) |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/8 | 2/8 | 4/8 | 0/8 |
| Abdominal painGastrointestinal disorders | 0/8 | 2/8 | 2/8 | 0/8 | 0/8 |
| FlatulenceGastrointestinal disorders | 0/8 | 0/8 | 0/8 | 2/8 | 0/8 |
| Abdominal discomfortGastrointestinal disorders | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 |
| Faeces softGastrointestinal disorders | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 |
| NauseaGastrointestinal disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 |
| Dizziness posturalNervous system disorders | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 0/8 | 0/8 | 1/8 | 1/8 | 0/8 |
| Infusion site erythemaGeneral disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 |
| Age, Continuous(Years) | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 | ESRD on Hemodialysis, Part 2 | Total |
|---|---|---|---|---|---|
| Mean | 61.5 ± 10.78 | 72.0 ± 7.05 | 61.4 ± 12.49 | 51.8 ± 7.09 | 61.6 ± 2.72 |
| Sex: Female, Male(Participants) | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 | ESRD on Hemodialysis, Part 2 | Total |
|---|---|---|---|---|---|
| Female | 3 | 1 | 4 | 1 | 9 |
| Male | 5 | 7 | 4 | 7 | 23 |
| Race/Ethnicity, Customized(Participants) | Normal, Part 1 | Moderate, Part 1 | Severe/ESRD Not on Hemodialysis, Part 1 | ESRD on Hemodialysis, Part 2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 1 | 1 | 2 | 8 | 12 |
| White: White/Caucasian/European | 7 | 6 | 5 | 0 | 18 |
| Multiple: African American/African/White | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jun 2016 to primary completion in Jun 2017, 11 months.
Results were first posted in Nov 2018, 1 year 5 months after primary completion.
Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 11 months is above that.
Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin